Thrivent Financial For Lutherans Altimmune, Inc. Transaction History

Thrivent Financial For Lutherans

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 19, 2021	SELL	$9.85 - $16.46 $396,393 - $662,399	-40,243 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$12.71 - $24.31 $66,041 - $126,314	-5,196 Reduced 11.44%	40,243 $569,000
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $356,241 - $646,142	45,439 New	45,439 $512,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $356M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.